The National Institutes of Health (NIH) is set to launch a major cancer vaccine development program in December, according to a report by The New York Times. This initiative aims to replicate the success of the Covid-19 vaccine development efforts by bringing together researchers and resources from various healthcare companies and nonprofits. The program will initially focus on pancreatic, liver, and colorectal cancers, as well as pediatric tumors.
Moderna, a leader in cancer vaccine research, has seen promising results from its experimental cancer therapy in recent clinical trials. On August 19, Moderna and Merck announced that their co-developed mRNA-based therapy, intismeran, when combined with Merck's Keytruda, increased the time before cancer returned or spread in patients with high-risk melanoma. These positive results are driving more resources toward cancer research, potentially accelerating Moderna's development timelines.
Shares of Moderna (NASDAQ:MRNA) surged more than 14% on Friday following the reports of the new cancer research initiative. The advancements in artificial intelligence (AI) and mRNA technology are enabling doctors to design personalized treatments tailored to each patient's immune system. However, before investing in Moderna, it's important to consider other potential high-growth stocks recommended by The Motley Fool Stock Advisor.